What the studies show
Approval-grade HbA1c reductions as an add-on in type 2 diabetes, with a particular effect on post-meal glucose because of its short action.
Several well-run randomised trials in people, pointing the same way. You can plan around this. It still says nothing about whether the effect is worth the side effects for you.
- 1Soliqua 100/33 prescribing information (insulin glargine and lixisenatide).DailyMedRegulatory status and pharmacokinetics.
In context
Lixisenatide is a short-acting GLP-1 receptor agonist derived from exendin-4, approved for type 2 diabetes since 2013 and now sold mainly in combination with insulin glargine. Its cardiovascular-outcomes trial in 6,068 people after a heart attack was neutral. In 2024 a French phase 2 trial found that a year of lixisenatide slowed motor progression in early Parkinson's disease by about three points on the standard scale, with nausea in nearly half. It is prescription-only; the standalone product has been withdrawn in some markets.
Lixisenatide is approved (rx). Legal status differs by country — see the regulation section or the jurisdiction pages.
Questions
Is Lixisenatide proven to help with blood glucose?
What studies are behind the grade?
Is Lixisenatide approved for this?
Other outcomes for Lixisenatide
- AMajor cardiovascular events1 large RCT (ELIXA, n=6,068)
- BMotor progression in early Parkinson's disease1 phase 2 RCT (n=156, 12 mo)
- AGI side effectsadverseAll trials
Written and maintained by LYO Research — how pages are written and checked. Reviewed 23 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →